{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:13Z","timestamp":1790659393754,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Soft tissue sarcomas (STS) comprise a heterogeneous group of mesenchymal malignancies with limited treatment options and poor outcomes in the advanced setting. Although immune checkpoint inhibitors have transformed the management of many solid tumors, their efficacy in STS has been modest and strongly histology dependent. This review aims to synthesize recent advances in immuno-oncology as applied to STS and to highlight emerging strategies that may overcome resistance and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Thus far, clinically meaningful activity of immune checkpoint inhibitors has been identified select STS subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma. Combination approaches incorporating immune checkpoint inhibitors with chemotherapy, radiation, tyrosine kinase inhibitors, or novel immune modulators have shown enhanced antitumor activity in early-phase and randomized trials. In parallel, engineered T-cell therapies targeting cancer-testis antigens have emerged as a standard-of-care option in synovial sarcoma and are being expanded to other histologies. Finally, advances in tumor microenvironment characterization, including the role of tertiary lymphoid structures and myeloid modulation, are refining patient selection and informing rational trial design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Immunotherapy continues to reshape the therapeutic landscape of soft tissue sarcoma. While immune checkpoint blockade alone benefits only a subset of patients, rational combination strategies and cellular therapies offer promising avenues to broaden clinical efficacy. Continued integration of biomarker-driven approaches, translational correlative studies, and histology-specific trial designs will be essential to fully realize the potential of immunotherapy in STS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01761-y","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:23:00Z","timestamp":1773742980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Revisiting the Immune Frontier in Soft Tissue Sarcomas"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-9319","authenticated-orcid":false,"given":"Nadeem","family":"Bilani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-1427","authenticated-orcid":false,"given":"Nourhane","family":"Al Akoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusul","family":"Al-Marayaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislav","family":"Alexiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Hermida","family":"de Viveiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-0607","authenticated-orcid":false,"given":"Seth M.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1761_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/EDBK_205423","volume":"38","author":"D Katz","year":"2018","unstructured":"Katz D, Palmerini E, Pollack SM. More than 50 subtypes of soft tissue sarcoma: paving the path for Histology-Driven treatments. Am Soc Clin Oncol Educ Book. 2018;38:925\u201338.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1761_CR2","doi-asserted-by":"publisher","first-page":"1199292","DOI":"10.3389\/fphar.2023.1199292","volume":"14","author":"Z Tian","year":"2023","unstructured":"Tian Z, Yao W. Chemotherapeutic drugs for soft tissue sarcomas: a review. Front Pharmacol. 2023;14:1199292.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1761_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.6004\/jnccn.2022.7027","volume":"20","author":"LB Banks","year":"2022","unstructured":"Banks LB, D\u2019Angelo SP. The role of immunotherapy in the management of soft tissue sarcomas: current landscape and future outlook. J Natl Compr Canc Netw. 2022;20(7):834\u201344.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1761_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-022-12762-z","volume":"30","author":"A Saif","year":"2023","unstructured":"Saif A, et al. A randomized trial of pembrolizumab & radiotherapy versus radiotherapy in High-Risk soft tissue sarcoma of the extremity (SU2C-SARC032). Ann Surg Oncol. 2023;30(2):683\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1761_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","volume":"20","author":"M von Mehren","year":"2022","unstructured":"von Mehren M, et al. Soft tissue Sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(7):815\u201333.","journal-title":"J Natl Compr Canc Netw"},{"key":"1761_CR6","unstructured":"National Comprehensive Cancer. N., NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma (Version 1) 2025."},{"issue":"1","key":"1761_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000369906","volume":"82","author":"NC Campanella","year":"2015","unstructured":"Campanella NC, et al. Absence of microsatellite instability in soft tissue sarcomas. Pathobiology. 2015;82(1):36\u201342.","journal-title":"Pathobiology"},{"key":"1761_CR8","doi-asserted-by":"publisher","first-page":"104055","DOI":"10.1016\/j.critrevonc.2023.104055","volume":"188","author":"F Poumeaud","year":"2023","unstructured":"Poumeaud F, et al. Special features of sarcomas developed in patients with Lynch syndrome: A systematic review. Crit Rev Oncol Hematol. 2023;188:104055.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"1761_CR9","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1172\/JCI139080","volume":"130","author":"JY Chan","year":"2020","unstructured":"Chan JY, et al. Multiomic analysis and Immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Invest. 2020;130(11):5833\u201346.","journal-title":"J Clin Invest"},{"issue":"4","key":"1761_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, et al. Doxorubicin alone versus intensified doxorubicin plus Ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415\u201323.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1761_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/ijc.34051","volume":"151","author":"Y Takeuchi","year":"2022","unstructured":"Takeuchi Y, et al. The landscape of genetic aberrations in Myxofibrosarcoma. Int J Cancer. 2022;151(4):565\u201377.","journal-title":"Int J Cancer"},{"issue":"2","key":"1761_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaoncol.2020.6564","volume":"7","author":"HJ Schmoll","year":"2021","unstructured":"Schmoll HJ, et al. Efficacy of pazopanib with or without gemcitabine in patients with Anthracycline- and\/or Ifosfamide-Refractory soft tissue sarcoma: final results of the PAPAGEMO phase 2 randomized clinical trial. JAMA Oncol. 2021;7(2):255\u201362.","journal-title":"JAMA Oncol"},{"issue":"30","key":"1761_CR13","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.20.00714","volume":"38","author":"V Gr\u00fcnwald","year":"2020","unstructured":"Gr\u00fcnwald V, et al. Randomized comparison of pazopanib and doxorubicin as First-Line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. J Clin Oncol. 2020;38(30):3555\u201364.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1761_CR14","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"7791","key":"1761_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556\u201360.","journal-title":"Nature"},{"issue":"3","key":"1761_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416\u201326.","journal-title":"Lancet Oncol"},{"issue":"10467","key":"1761_CR17","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","volume":"404","author":"YM Mowery","year":"2024","unstructured":"Mowery YM, et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Lancet. 2024;404(10467):2053\u201364.","journal-title":"Lancet"},{"issue":"4","key":"1761_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s43018-024-00726-z","volume":"5","author":"CL Roland","year":"2024","unstructured":"Roland CL, et al. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint Blockade in retroperitoneal dedifferentiated liposarcoma and extremity\/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024;5(4):625\u201341.","journal-title":"Nat Cancer"},{"key":"1761_CR19","doi-asserted-by":"crossref","unstructured":"Wagner MJ et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 Blockade in rare tumors (DART). J Immunother Cancer. 2021;9(8).","DOI":"10.1136\/jitc-2021-002990"},{"issue":"18","key":"1761_CR20","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1002\/cncr.34370","volume":"128","author":"V Ravi","year":"2022","unstructured":"Ravi V, et al. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022;128(18):3383\u201391.","journal-title":"Cancer"},{"key":"1761_CR21","doi-asserted-by":"publisher","first-page":"115537","DOI":"10.1016\/j.ejca.2025.115537","volume":"224","author":"Y Fujisawa","year":"2025","unstructured":"Fujisawa Y, et al. Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: efficacy of nivolumab (AngioCheck Study). Eur J Cancer. 2025;224:115537.","journal-title":"Eur J Cancer"},{"issue":"16","key":"1761_CR22","first-page":"11503","volume":"41","author":"JB Allred","year":"2023","unstructured":"Allred JB, et al. A multicenter phase II study of cabozantinib\u2009+\u2009nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). J Clin Oncol. 2023;41(16):11503.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1761_CR23","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.esmoop.2023.101618","volume":"8","author":"JY Blay","year":"2023","unstructured":"Blay JY, et al. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies. ESMO Open. 2023;8(5):101618.","journal-title":"ESMO Open"},{"issue":"4","key":"1761_CR24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/1078-0432.CCR-24-3485","volume":"31","author":"AQ Lee","year":"2025","unstructured":"Lee AQ, et al. Histologic and Immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma. Clin Cancer Res. 2025;31(4):678\u201384.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1761_CR25","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.20.03452","volume":"40","author":"SP Chawla","year":"2022","unstructured":"Chawla SP, et al. Phase II randomized study of CMB305 and Atezolizumab compared with Atezolizumab alone in Soft-Tissue sarcomas expressing NY-ESO-1. J Clin Oncol. 2022;40(12):1291\u2013300.","journal-title":"J Clin Oncol"},{"key":"1761_CR26","first-page":"1","volume":"4","author":"MJ Scanlan","year":"2004","unstructured":"Scanlan MJ, Simpson AJ, Old LJ. The cancer\/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.","journal-title":"Cancer Immun"},{"key":"1761_CR27","doi-asserted-by":"crossref","unstructured":"Fradin JJ, Charlson JA. Review of adoptive cellular therapies for the treatment of sarcoma. Cancers (Basel). 2025;17(8).","DOI":"10.3390\/cancers17081302"},{"issue":"10435","key":"1761_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460\u201371.","journal-title":"Lancet"},{"issue":"24","key":"1761_CR29","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","volume":"29","author":"A Kawai","year":"2023","unstructured":"Kawai A, et al. Safety and efficacy of NY-ESO-1 Antigen-Specific T-Cell receptor Gene-Transduced T lymphocytes in patients with synovial sarcoma: A phase I\/II clinical trial. Clin Cancer Res. 2023;29(24):5069\u201378.","journal-title":"Clin Cancer Res"},{"key":"1761_CR30","doi-asserted-by":"crossref","unstructured":"Schroeder BA et al. CD4\u2009+\u2009T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. J Immunother Cancer. 2021;9(8).","DOI":"10.1136\/jitc-2021-002812"},{"issue":"11","key":"1761_CR31","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1158\/1078-0432.CCR-22-0240","volume":"28","author":"MJ Wagner","year":"2022","unstructured":"Wagner MJ, et al. A phase 1\/2 trial combining avelumab and trabectedin for advanced liposarcoma and leiomyosarcoma. Clin Cancer Res. 2022;28(11):2306\u201312.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1761_CR32","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","volume":"41","author":"RL Jones","year":"2005","unstructured":"Jones RL, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41(18):2853\u201360.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1761_CR33","doi-asserted-by":"publisher","first-page":"e205865","DOI":"10.1001\/jamaoncol.2020.5865","volume":"7","author":"J Lansu","year":"2021","unstructured":"Lansu J, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: A nonrandomized controlled trial. JAMA Oncol. 2021;7(1):e205865.","journal-title":"JAMA Oncol"},{"issue":"18","key":"1761_CR34","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1002\/cncr.27446","volume":"118","author":"SM Pollack","year":"2012","unstructured":"Pollack SM, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid\/round cell liposarcoma. Cancer. 2012;118(18):4564\u201370.","journal-title":"Cancer"},{"issue":"15","key":"1761_CR35","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1200\/JCO-24-01466","volume":"43","author":"SP D\u2019Angelo","year":"2025","unstructured":"D\u2019Angelo SP, et al. Letetresgene autoleucel in Advanced\/Metastatic Myxoid\/Round cell liposarcoma. J Clin Oncol. 2025;43(15):1777\u201388.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1761_CR36","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke M, et al. Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2025;31(7):2365\u201374.","journal-title":"Nat Med"},{"key":"1761_CR37","doi-asserted-by":"crossref","unstructured":"Cope BM et al. Targeting the molecular and Immunologic features of leiomyosarcoma. Cancers (Basel). 2023;15(7).","DOI":"10.3390\/cancers15072099"},{"issue":"11","key":"1761_CR38","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"L D\u2019Ambrosio","year":"2020","unstructured":"D\u2019Ambrosio L, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European organization for research and treatment of cancer soft tissue and bone sarcoma group. Cancer. 2020;126(11):2637\u201347.","journal-title":"Cancer"},{"key":"1761_CR39","doi-asserted-by":"crossref","unstructured":"Reichardt P et al. Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc). American Society of Clinical Oncology. 2023","DOI":"10.1200\/JCO.2023.41.16_suppl.11500"},{"issue":"3","key":"1761_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1200\/JCO.24.00358","volume":"43","author":"J Martin-Broto","year":"2025","unstructured":"Martin-Broto J, et al. Phase Ib study for the combination of Doxorubicin, Dacarbazine, and nivolumab as the upfront treatment in patients with advanced leiomyosarcoma: A study by the Spanish sarcoma group (GEIS). J Clin Oncol. 2025;43(3):297\u2013307.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1761_CR41","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423\u201332.","journal-title":"Lancet Oncol"},{"issue":"14","key":"1761_CR42","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1158\/0008-5472.CAN-23-2115","volume":"84","author":"E Sicinska","year":"2024","unstructured":"Sicinska E, et al. ASPSCR1::TFE3 drives alveolar soft part sarcoma by inducing targetable transcriptional programs. Cancer Res. 2024;84(14):2247\u201364.","journal-title":"Cancer Res"},{"issue":"10","key":"1761_CR43","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen AP, et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med. 2023;389(10):911\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"1761_CR44","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","volume":"24","author":"JY Blay","year":"2023","unstructured":"Blay JY, et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 2023;24(8):892\u2013902.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1761_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","volume":"20","author":"BA Wilky","year":"2019","unstructured":"Wilky BA, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(6):837\u201348.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1761_CR46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/PAS.0b013e31814b18fb","volume":"32","author":"M Hisaoka","year":"2008","unstructured":"Hisaoka M, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol. 2008;32(3):452\u201360.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1761_CR47","doi-asserted-by":"publisher","first-page":"p100522","DOI":"10.1016\/j.esmoop.2022.100522","volume":"7","author":"A Smrke","year":"2022","unstructured":"Smrke A, et al. Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the world sarcoma network. ESMO Open. 2022;7(3):p100522.","journal-title":"ESMO Open"},{"issue":"22","key":"1761_CR48","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1002\/cncr.35483","volume":"130","author":"T Nishikawa","year":"2024","unstructured":"Nishikawa T, et al. Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial\/NCCH1510). Cancer. 2024;130(22):3836\u201344.","journal-title":"Cancer"},{"key":"1761_CR49","doi-asserted-by":"crossref","unstructured":"Xiao K, Yang K, Hirbe AC. A sequencing overview of malignant peripheral nerve sheath tumors: findings and implications for treatment. Cancers (Basel). 2025;17(2).","DOI":"10.3390\/cancers17020180"},{"issue":"24","key":"1761_CR50","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","volume":"30","author":"S Movva","year":"2024","unstructured":"Movva S, et al. Histology-Specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma. Clin Cancer Res. 2024;30(24):5612\u20139.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1761_CR51","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.5858\/arpa.2023-0552-OA","volume":"148","author":"PM Hammer","year":"2024","unstructured":"Hammer PM, et al. Perivascular epithelioid Cell-Family tumors in Children, Adolescents, and young adults: clinicopathologic features in 70 cases. Arch Pathol Lab Med. 2024;148(11):e374\u201385.","journal-title":"Arch Pathol Lab Med"},{"key":"1761_CR52","doi-asserted-by":"crossref","unstructured":"Reinhorn D, et al. Clinical activity of immune checkpoint Blockade in advanced perivascular epithelioid cell neoplasms (PEComas): A retrospective single center study. American Society of Clinical Oncology; 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.11553"},{"key":"1761_CR53","doi-asserted-by":"crossref","unstructured":"Abdelmogod A et al. A matched molecular and clinical analysis of the epithelioid haemangioendothelioma cohort in the Stafford Fox rare cancer program and contextual literature review. Cancers (Basel), 2023. 15(17).","DOI":"10.3390\/cancers15174378"},{"key":"1761_CR54","unstructured":"Measuring if immunotherapy plus chemotherapy is better than chemotherapy alone for patients with aggressive poorly dfferentiated sarcomas. 2025."},{"key":"1761_CR55","unstructured":"First-line trabectedin with ipilimumab\u2009+\u2009nivolumab in soft tissue sarcoma (SAINT study). 2025."},{"key":"1761_CR56","unstructured":"Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas (PEMBROCABOSARC). 2025."},{"key":"1761_CR57","unstructured":"Testing the addition of cemiplimab to palbociclib for the treatment of advanced dedifferentiated liposarcoma. 2025."},{"key":"1761_CR58","unstructured":"D\u2019Angelo SP. A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma. in ASCO Abstracts & Presentations. 2025."},{"issue":"7668","key":"1761_CR59","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, et al. CDK4\/6 Inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135.","journal-title":"Nature"},{"issue":"10","key":"1761_CR60","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","volume":"11","author":"M Heckler","year":"2021","unstructured":"Heckler M, et al. Inhibition of CDK4\/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021;11(10):2564\u201381.","journal-title":"Cancer Discov"},{"issue":"11","key":"1761_CR61","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO-24-02524","volume":"43","author":"BA Wilky","year":"2025","unstructured":"Wilky BA, et al. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with Relapsed\/Refractory metastatic sarcomas. J Clin Oncol. 2025;43(11):1358\u201368.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1761_CR62","doi-asserted-by":"publisher","first-page":"p102254","DOI":"10.1016\/j.esmoop.2024.102254","volume":"9","author":"N Lakhani","year":"2024","unstructured":"Lakhani N, et al. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101). ESMO Open. 2024;9(4):p102254.","journal-title":"ESMO Open"},{"issue":"10","key":"1761_CR63","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/s41416-023-02431-7","volume":"129","author":"D Day","year":"2023","unstructured":"Day D, et al. A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer. Br J Cancer. 2023;129(10):1608\u201318.","journal-title":"Br J Cancer"},{"key":"1761_CR64","unstructured":"Bintrafusp alfa and doxorubicin hydrochloride in treating patients with advanced sarcoma (TRUST Study). 2025."},{"key":"1761_CR65","doi-asserted-by":"crossref","unstructured":"Lan Y et al. Colocalized targeting of TGF-\u03b2 and PD-L1 by bintrafusp Alfa elicits distinct antitumor responses. J Immunother Cancer 2022;10(7).","DOI":"10.1136\/jitc-2021-004122"},{"issue":"8","key":"1761_CR66","doi-asserted-by":"publisher","first-page":"105522","DOI":"10.1016\/j.esmoop.2025.105522","volume":"10","author":"E Rosenbaum","year":"2025","unstructured":"Rosenbaum E, et al. A phase I study of the CSF1R inhibitor Vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma. ESMO Open. 2025;10(8):105522.","journal-title":"ESMO Open"},{"issue":"15","key":"1761_CR67","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-19-3416","volume":"26","author":"L Chen","year":"2020","unstructured":"Chen L, et al. The immunosuppressive niche of Soft-Tissue sarcomas is sustained by Tumor-Associated macrophages and characterized by intratumoral tertiary lymphoid structures. Clin Cancer Res. 2020;26(15):4018\u201330.","journal-title":"Clin Cancer Res"},{"key":"1761_CR68","doi-asserted-by":"crossref","unstructured":"Blum Murphy MA, et al. Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer. American Society of Clinical Oncology. 2023.","DOI":"10.1200\/JCO.2023.41.4_suppl.349"},{"issue":"41","key":"1761_CR69","doi-asserted-by":"publisher","first-page":"e2507542122","DOI":"10.1073\/pnas.2507542122","volume":"122","author":"J Hu","year":"2025","unstructured":"Hu J, et al. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proc Natl Acad Sci U S A. 2025;122(41):e2507542122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1761_CR70","doi-asserted-by":"crossref","unstructured":"Chen R. Tumour\u2013infiltrating lymphocyte therapy landscape. [journal] 2025.","DOI":"10.1136\/bmjonc-2024-000566"},{"issue":"45","key":"1761_CR71","doi-asserted-by":"publisher","first-page":"e2409560122","DOI":"10.1073\/pnas.2409560122","volume":"122","author":"R Falahat","year":"2025","unstructured":"Falahat R, Mul\u00e9 JJ. Chemokine\/cytokine-releasing biomaterials induce in situ tertiary lymphoid-like structures and enhance antitumor immunity. Proc Natl Acad Sci U S A. 2025;122(45):e2409560122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1761_CR72","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41467-024-55430-4","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, et al. Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy. Nat Commun. 2025;16(1):44.","journal-title":"Nat Commun"},{"issue":"1","key":"1761_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-024-01946-8","volume":"23","author":"M Toulmonde","year":"2024","unstructured":"Toulmonde M, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide. Mol Cancer. 2024;23(1):38.","journal-title":"Mol Cancer"},{"key":"1761_CR74","doi-asserted-by":"publisher","first-page":"1116937","DOI":"10.3389\/fonc.2023.1116937","volume":"13","author":"SP Chawla","year":"2023","unstructured":"Chawla SP, et al. Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311). Front Oncol. 2023;13:1116937.","journal-title":"Front Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01761-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01761-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01761-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:02:44Z","timestamp":1773788564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01761-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1761"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01761-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}